AAN REVIEW: Imaging and biomarkers dominate
This article was originally published in Clinica
Executive Summary
Parkinson's and Alzheimer's disease presentations at the 65th American Academy of Neurology (AAN) Annual Meeting in San Diego from 16 to 23 March tended toward imaging and biomarker studies rather than clinical trial data for therapeutics.